Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast

Indian Journal of Cancer

Volumn 50, Issue 3, 2013, Pages 239-244

  Rathore, A S ^a   Kumar, S ^a,b   Konwar, R ^c   Srivastava, A N ^d   Makker, A ^a   Goel, M M ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

^d Era's Lucknow Medical College and Hospital   (India)

Author keywords

Breast cancer; CD3; infiltrating ductal carcinoma; intra tumoral T cells; stromal T cells; tumor infiltrating lymphocytes

Indexed keywords

CD3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CD3+ T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MENOPAUSE; OVERALL SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84885400515     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.118744     Document Type: Article

References (31)

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001;2:133-40.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010;127:2893-917.
3. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumours predict clinical outcome. Science 2006;313:1960-4.
4. Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H, et al. Intraepithelial CD8+ T cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: Possible association with suppression of micrometastasis. Br J Cancer 2004;91:1711-7.
5. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
6. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001;61:3932-6.
7. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Res 2001;61:5132-6.
8. Hadden JW. The immunology and immunotherapy of breast cancer: An update. Int J Immunopharmacol 1999;21:79-101.
9. Rabinowich H, Cohen R, Bruderman I, Steiner Z, Klajman A. Functional analysis of mononuclear cell infiltrating into tumours: Lysis of autologous human tumour cells by cultured infiltrating lymphocytes. Cancer Res 1987;47:173-7.
10. Topalian SL, Solomon D, Rosenberg SA. Tumour-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142:3714-25.
11. Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GO, Papamichail M. Tumour specific cytolysis by tumour infiltrating lymphocytes in breast cancer. Cancer 1994;74:1275-82.
12. Toso JF, Oei C, Oshidari F, Tartaglia J, Paoletti E, Lyerly HK, et al. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumour-infiltrating lymphocytes from a patient with breast cancer: Characterization and antigen-specific activation. Cancer Res 1996;56:16-20.
13. Black MM, Speer FD, Opler SR. Structural representations of tumour host relationship in mammary carcinoma: Biologic and prognostic significance. Am J Clin Pathol 1956;26:250-65.
14. Shimokawara I, Imamura M, Yamanaka N, Ishii Y, Kikuchi K. Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: An immunoperoxidase study with anti-human T-and B-cell sera. Cancer 1982;49:1456-64.
15. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992;28A:859-64.
16. Di Giorgio A, Mingazzini P, Sammartino P, Canavese A, Arnone P, Scarpini M. Host defense and survival in patients with lung carcinoma. Cancer 2000;89:2038-45.
17. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumour infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-10.
18. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
19. Raspollini MR, Castiglione F, Rossi Degl'innocenti D, Amunni G, Villanucci A, Garbini F, et al. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 2005;16:590-6.
20. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
21. Guo X, Fan Y, Lang R, Gu F, Chen L, Cui L, et al. Tumor infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast. Mod Pathol 2008;21:1101-7.
22. Hussein MR, Hassan HI. Analysis of the mononuclear inflammatory cell infiltrates in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: Preliminary observations. J Clin Pathol 2006;59:972-7.
23. Rapin V, Contesso G, Mouriesse H, Bertin F, Lacombe MJ, Piekarski JD, et al. Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 1998;61:2503-10.
24. Wargotz ES, Silverberg SG. Medullary carcinoma of the breast: A clinicopathologic study with appraisal of current diagnostic criteria. Hum Pathol 1988;19:1340-6.
25. Ridolfi RL, Rosen PP, Port A, Kinne D, Mikι V. Medullary carcinoma of the breast: A clinicopathologic study with 10-year follow-up. Cancer 1997;40:1365-85.
26. Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, et al. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 2002;169:1829-36.
27. Nzula S, Going JJ, Stott DI. Antigen driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 2003;63:3275-80.
28. Al-Attar A, Shehata M, Durrant L, Moseley P, Deen S, Chan S. T Cell Density and location can influence the prognosis of ovarian cancer. Pathol Oncol Res 2010;16:361-70.
29. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71.
30. Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer:A double-edged sword. Cancer Cell 2007;12:300-1.
31. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007;67:585-92.